According to Next Move Strategy Consulting, the synthetic biology market is experiencing a period of unprecedented growth, with a projected market size of USD 66.29 billion by 2030, growing at a compound annual growth rate (CAGR) of 23.4% by 2030. This expansion is driven by the increased application of synthetic biology across various industries, including healthcare, agriculture, chemicals, energy, and environmental sectors.
The Synthetic Biology Market encompasses the design and construction of new biological systems and the re-design of existing natural biological systems for practical applications. As advancements in genetic engineering, DNA synthesis, and bioinformatics take center stage, synthetic biology is becoming a catalyst for innovation across numerous sectors, particularly in drug discovery, agriculture, bio-based chemicals, and biofuels.
Test It First – Download Your FREE Sample!
Market Overview
The global synthetic biology market was valued at USD 15.23 billion in 2023. A key driver of growth in the sector is the increasing adoption of synthetic biology formulations in healthcare. By enabling tailored gene therapies and personalized treatments, synthetic biology is revolutionizing the approach to complex diseases such as cancer and cardiovascular conditions.
A notable collaboration exemplifying the potential of synthetic biology in healthcare occurred in June 2024 when the University of Texas MD Anderson Cancer Center joined forces with Rice University to leverage genome engineering technologies to improve cancer research and treatment. Additionally, in September 2023, Osaka University developed a new gene-editing technique, NICER, which addresses the limitations of the widely used CRISPR/Cas9 gene-editing technology, demonstrating the innovation driving the sector.
Further boosting market growth, leading pharmaceutical companies like Vertex Pharmaceuticals and Fermbox Bio Pvt Ltd are investing heavily in advanced synthetic biology techniques. Vertex Pharmaceuticals launched exa-cel in December 2023, a cutting-edge gene-editing therapy for sickle cell disease, while Fermbox Bio’s Synbio product pipeline for transforming agricultural waste into 2G ethanol shows how synthetic biology is being integrated into sustainable practices.
The market is also benefiting from an increasing focus on food production innovations, with companies exploring synthetic biology’s role in developing engineered yeasts and bacteria to improve flavors, nutrition, and sustainability. A prime example of this innovation is Novozymes’ launch of Innova Delta in February 2024, a yeast technology designed to support the production of renewable ethanol from corn.
Technological Advancements
Technological advancements are key to the growth of the synthetic biology market. Innovations such as genome engineering techniques like CRISPR-Cas9 and TALENs, alongside the integration of Artificial Intelligence (AI) into synthetic biology, are transforming the landscape. AI is being used to optimize genetic designs, accelerate biological pathway development, and predict organism behavior.
Download Sample of Artificial Intelligence (AI) Market
Another area of focus is waste transformation, where synthetic biology is being employed to develop systems capable of breaking down or recycling waste materials, further underlining its environmental potential.
Market Segmentation
The synthetic biology market is segmented based on products, technologies, applications, and regions.
By Products:
- Synthetic DNA
- Synthetic Genes
- Chassis Organisms
- Oligonucleotides
- Cloning Technology Kits
- Enzymes
By Technology:
- Gene Synthesis
- Genome Engineering
- CRISPR-Cas9
- TALENs
- Bioinformatics
- Bio-sensors
By Application:
- Industrial Biotechnology
- Agriculture
- Environmental
- Energy
- Food & Beverage
- Healthcare
- Drug Discovery
- Diagnostics
- Therapeutics
- Pharmaceuticals
- Chemicals
- Specialty Chemicals
- Bio-based Chemicals
By Region:
- North America
- Europe
- Asia-Pacific
- Rest of the World
Geographical Insights
North America continues to dominate the synthetic biology market, driven by a well-established industrial biotechnology sector and a robust biotech innovation landscape. The U.S. biotech sector alone generated nearly USD 3 trillion in 2021, underscoring its integral role in driving market growth. Key players such as Ginkgo Bioworks, Thermo Fisher Scientific, and Agilent Technologies are leading efforts to integrate synthetic biology into sectors such as healthcare, agriculture, and sustainability.
On the other hand, Asia-Pacific is the fastest-growing region for synthetic biology. Countries like China and India are ramping up their investments in healthcare and biotechnology, creating opportunities for synthetic biology to play a critical role in the development of personalized medicine and innovative therapies. As reported by the World Bank Group, China’s healthcare expenditure as a percentage of GDP rose from 4.7% in 2014 to 5.4% in 2021, driving investments in biotechnological advancements.
Governments in South Korea and Japan are also pushing the envelope in synthetic biology research. In November 2023, South Korea’s Ministry of Science and ICT launched the National Synthetic Biology Initiative, aiming to foster the development of synthetic biology and enhance biomanufacturing capabilities in the region.
Competitive Landscape
The synthetic biology industry features numerous established players, including Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies Inc., Novozymes A/S, Ginkgo Bioworks, Amyris Inc., Precigen Inc., GenScript Biotech Corporation, Twist Bioscience, and Synthetic Genomics Inc. These companies are leveraging various strategies, such as product launches, mergers, and acquisitions, to expand their market presence.
Notable recent developments include:
- Ginkgo Bioworks: In May 2024, Ginkgo Bioworks formed a partnership with Sojitz Corporation to drive research and development in synthetic biology, addressing environmental challenges and promoting sustainability within Japan’s manufacturing sector.
- Merck KGaA: Merck expanded its capabilities in biologic therapies by partnering with Pearl Bio in March 2024. The collaboration focuses on creating biologics for cancer treatment, using synthetic biology techniques.
- Novozymes A/S: In September 2023, Novozymes introduced Vertera ProBite, an innovation for enhancing the plant-based meat industry by improving texture and enabling consumer-friendly labels.
Market Challenges
Despite the promising growth, the synthetic biology market faces challenges that may hinder its development. The high upfront costs associated with developing and deploying synthetic biology technologies, coupled with time-consuming R&D processes, remain barriers for some companies. These hurdles could potentially delay the widespread adoption of synthetic biology solutions.
Conclusion
The global synthetic biology market is poised for robust growth, fueled by ongoing innovations, expanding applications, and increasing investments across sectors such as healthcare, agriculture, chemicals, and energy. With the rise of AI integration, advancements in genetic engineering, and the potential for environmental sustainability, the market’s future is promising.
As the demand for sustainable and innovative solutions continues to grow, synthetic biology is at the forefront of shaping the future of biotechnological advances, creating new opportunities for healthcare solutions, bio-based products, and environmental applications. The market is expected to thrive, with key players and governments accelerating research and development efforts to capitalize on this transformative field.
